Author:
Conant Genevieve,Lai Benjamin Fook Lun,Lu Rick Xing Ze,Korolj Anastasia,Wang Erika Yan,Radisic Milica
Funder
Natural Sciences and Engineering Research Council of Canada
Ontario Council on Graduate Studies, Council of Ontario Universities
Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology
Reference116 articles.
1. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33.
2. Mullard, A. (2015). 2014 FDA drug approvals. Nature Reviews. Drug Discovery, 14(2), 77–81.
3. Research C for DE and. Drug Innovation - Novel Drugs Summary 2016 [Internet]. [cited 2017 Apr 4];Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm534863.htm
4. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery, 3(8), 711–716.
5. Arrowsmith, J., & Miller, P. (2013). Trial watch: Phase II and phase III attrition rates 2011-2012. Nature Reviews. Drug Discovery, 12(8), 569–569.
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献